Alnylam Pharmaceuticals Inc (ALNY)vsBiodexa Pharmaceticals (BDRX)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
BDRX
Biodexa Pharmaceticals
$3.36
-2.04%
HEALTHCARE · Cap: $2.68M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 5164867% more annual revenue ($4.29B vs $83,000). ALNY leads profitability with a 12.6% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
BDRX
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Intrinsic value data unavailable for BDRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : BDRX
The strongest argument for BDRX centers on Price/Book, Debt/Equity.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : BDRX
The primary concerns for BDRX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ALNY profiles as a growth stock while BDRX is a value play — different risk/reward profiles.
BDRX carries more volatility with a beta of 1.16 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 24/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Biodexa Pharmaceticals
HEALTHCARE · BIOTECHNOLOGY · USA
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in the United Kingdom, rest of Europe, and internationally. The company is headquartered in Cardiff, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?